Demographic characteristics of study participants (n = 16)
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 46.5 (34-77) |
| Sex | |
| Male | 6 (38%) |
| Female | 10 (62%) |
| Serum LDH | |
| Normal | 12 (75%) |
| Elevated | 3 (19%) |
| Unknown | 1 (6%) |
| Histology | |
| Follicular | 12 (75%) |
| Transformed follicular | 3 (19%) |
| Small lymphocytic | 1 (6%) |
| Maximum tumor diameter | |
| > 50 mm | 5 (31%) |
| < 50 mm | 11 (9%) |
| No. of nodal sites > 5 | 11 (69%) |
| FLIPI index, mean score (range) | 2.75 (0-3) |
| ECOG performance status | |
| 0 | 8 |
| 1 | 7 |
| 2 | 1 |
| Bone marrow involvement | |
| > 25% | 1 (6%) |
| 11%-25% | 4 (25%) |
| 1%-10% | 5 (31%) |
| None | 6 (38%) |
| Number of previous chemotherapy regimens, median (range) | 2 (1-4) |
| Prior rituximab | |
| Yes (4/7 rituximab refractory) | 7 (44%) |
| No | 9 (56%) |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 46.5 (34-77) |
| Sex | |
| Male | 6 (38%) |
| Female | 10 (62%) |
| Serum LDH | |
| Normal | 12 (75%) |
| Elevated | 3 (19%) |
| Unknown | 1 (6%) |
| Histology | |
| Follicular | 12 (75%) |
| Transformed follicular | 3 (19%) |
| Small lymphocytic | 1 (6%) |
| Maximum tumor diameter | |
| > 50 mm | 5 (31%) |
| < 50 mm | 11 (9%) |
| No. of nodal sites > 5 | 11 (69%) |
| FLIPI index, mean score (range) | 2.75 (0-3) |
| ECOG performance status | |
| 0 | 8 |
| 1 | 7 |
| 2 | 1 |
| Bone marrow involvement | |
| > 25% | 1 (6%) |
| 11%-25% | 4 (25%) |
| 1%-10% | 5 (31%) |
| None | 6 (38%) |
| Number of previous chemotherapy regimens, median (range) | 2 (1-4) |
| Prior rituximab | |
| Yes (4/7 rituximab refractory) | 7 (44%) |
| No | 9 (56%) |
ECOG indicates Eastern Cooperative Oncology Group.